|
|
| (12 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
|
| |
|
| == Initial assessment and risk stratification ==
| | {{CMG}}; {{AE}} |
| {| class="wikitable" | |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen" |'''Strong recommendation'''
| |
| |-
| |
| | bgcolor="LightGreen" |1. Hemodynamic status should be assessed immediately upon presentation and resuscitative measures begun as needed.
| |
| |-
| |
| |}
| |
|
| |
|
| {| class="wikitable"
| | == Demographic / Medical history == |
| |-
| | * '''Demographic''': 77, M |
| | colspan="1" style="text-align:center; background:LemonChiffon" |'''Conditional recommendation'''
| | * '''Past Medical History:''' HTN, BPH, CAD w CABG, MI, AVR |
| |-
| | * '''Past Surgical History:''' |
| | bgcolor="LemonChiffon" |1.Blood transfusions should target hemoglobin ≥ 7 g / dl, with higher hemoglobins targeted in patients with clinical evidence of intravascular volume depletion or comorbidities, such as coronary artery disease.
| | ** AVR (#25 magna ease valve) on 12/14/17 |
| 2. Risk assessment should be performed to stratify patients into higher and lower risk categories and may assist in initial decisions such as the timing of endoscopy, time of discharge, and level of care.
| | ** Stent on 10/10/2017 |
| | ** CABG in 2007 |
| | ** Appendectomy in 1957 |
|
| |
|
| 3. Discharge from the emergency department without inpatient endoscopy may be considered in patients with urea nitrogen < 18.2 mg / dl; hemoglobin ≥ 13.0 g / dl for men (12.0 g / dl for women), systolic blood pressure ≥ 110 mm Hg; pulse 100 beats / min; and absence of melena, syncope, cardiac failure, and liver disease, as they have <1 % chance of requiring intervention.
| | * '''Medications:''' |
| | ** Metoprolol |
| | ** DAPT |
| | ** Tamsulosin |
|
| |
|
| |-
| | == Procedure == |
| |}
| | * '''Index Procedure Date/Time''': |
| == Pre-endoscopic medical therapy == | | ** mm/dd/YYYY at xx:xx [insert date and time] |
| {| class="wikitable" style="width:82%"
| | * '''Index Procedure Detail''': |
| |-
| | ** On mm/dd/YYYY at xx:xx [insert date and time] the subject underwent a [select surgical correction] for [select etiology]. |
| | colspan="1" style="text-align:center; background:LemonChiffon" |'''Conditional recommendation'''
| | ** Access site details |
| |-
| | ** The site reported that there were/were not procedural complication(s). |
| | bgcolor="LemonChiffon" |1. Intravenous infusion of erythromycin (250 mg ~ 30 min before endoscopy) should be considered to improve diagnostic yield and decrease the need for
| |
|
| |
|
| repeat endoscopy. However, erythromycin has not consistently been shown to improve clinical outcomes
| | == Event(s) == |
| | '''Event (1):''' |
| | * '''Site Reported Event Onset Date: 12/26/2017''' |
|
| |
|
| |-
| | * '''Event summary''': |
| | bgcolor="LemonChiffon" |2. Pre-endoscopic intravenous PPI (e.g., 80 mg bolus followed by 8 mg / h infusion) may be considered to decrease the proportion of patients who have
| | ** Symptoms and sign: Subject presented with |
| | *** Right leg collapse, |
| | *** Right arm and right leg weakness |
| | ** Episodes lasted approximately 2 -10 minutes and ranged from 1-4/day |
| | ** No visual or speech difficulties, no headache or neck pain |
| | ** No history of vertigo, syncope, loss of consciousness or seizures |
| | ** Other important symptoms related to the chief complaint. |
| | ** Physical assessment: |
| | *** Normal neurological exam |
| | *** BP: 124/66 |
| | *** HR: 96 |
| | == Laboratory data == |
| | * '''Lab studies list: ('''Date/ name/ value) |
| | ** 01/04/2018 / HDLC / 31 |
| | ** 01/03/2018 / INR / 1.2 |
|
| |
|
| higher risk stigmata of hemorrhage at endoscopy and who receive endoscopic therapy. However, PPIs do not improve clinical outcomes such as further
| | == Diagnostic tests == |
| | | * 01/03/2018 '''TTE''' |
| bleeding, surgery, or death
| | ** Mild left ventricular hypertrophy with normal systolic function and left ventricular diastolic dysfunction |
| |-
| | ** Moderate left atrial enlargement |
| | bgcolor="LemonChiffon" |3. If endoscopy will be delayed or cannot be performed, intravenous PPI is recommended to reduce further bleeding.
| | ** Bioprosthetic aortic valve peak vel 2 m/s and mean grad 6.4 hg, no AI |
| |-
| | * 01/03/2018 '''MR Brain''' |
| |}
| | ** NO evidence of vascular occlusion |
| | | ** No evidence of restricted diffusion to suggest infarction |
| == Gastric lavage == | | * 01/03/2018 '''MRA H/N''' |
| {| class="wikitable"
| | ** Eccentric filling defect in the left internal carotid artery just distil to the bifurcation that may be from calcification / nonocclusive thrombus |
| |-
| | * 01/03/2018 '''Carotid US(Preliminary)''' |
| | colspan="1" style="text-align:center; background:LemonChiffon" |'''Conditional recommendation'''
| | ** Right: 1-49% stenosis of right internal carotid |
| |-
| | ** Left: 1-49% stenosis of left internal carotid |
| | bgcolor="LemonChiffon" |1. Nasogastric or orogastric lavage is not required in patients with UGIB for diagnosis, prognosis, visualization, or therapeutic effect
| | ** Bilateral vrtebral arteries patent with antegrade flow |
| |-
| | * 01/03/2018 '''EEG''' |
| |}
| | ** Normal awake EEG |
| | | ** No epilitiform discharges, focal changes or other abnormalities |
| == Timing of endoscopy ==
| | ==Consults== |
| {| class="wikitable" style="width:82%"
| | *Neurology consult : 01/03/2018 |
| |-
| | *Recommendations: |
| | colspan="1" style="text-align:center; background:LemonChiffon" |'''Conditional recommendation'''
| | **CBC,CMP |
| |-
| | **Admission to neurology service |
| | bgcolor="LemonChiffon" |Timing of endoscopy
| | **MRI brain with or without contrast |
| 1. Patients with UGIB should generally undergo endoscopy within 24 h of admission, following resuscitative efforts to optimize hemodynamic parameters and
| | **MRA of the extracranial and intracranial circulation |
| | | **Carotid duplex US |
| other medical problems.
| | **EEG |
| |-
| | *Date and time of consult |
| | bgcolor="LemonChiffon" |2. In patients who are hemodynamically stable and without serious comorbidities endoscopy should be performed as soon as possible in a non-emergent
| | *Suggested treatments: |
| setting to identify the substantial proportion of patients with low-risk endoscopic fi ndings who can be safely discharged.
| | **Aspirin 81mg chew tab |
| |-
| | **Clopidogrel 75 mg tab |
| | bgcolor="LemonChiffon" |3. In patients with higher risk clinical features (e.g., tachycardia, hypotension, bloody emesis or nasogastric aspirate in hospital) endoscopy within 12 h may
| | **Enoxaparin 40mg inj |
| | | **Metoprolol succinate 25mg extended release |
| be considered to potentially improve clinical outcomes.
| | ==Clinical course== |
| |-
| | * |
| |}
| | *Date and time of events, |
| | | *Patient condition got worse or better. |
| ==Endoscopic diagnosis==
| | ==Treatment and outcome== |
| | | *List of relevant medical treatments |
| {| class="wikitable"
| | **Aspirin 81mg chew tab |
| |-
| | **Clopidogrel 75 mg tab |
| | colspan="1" style="text-align:center; background:LightGreen" |'''Strong recommendation'''
| | **Enoxaparin 40mg inj |
| |-
| | **Metoprolol succinate 25mg extended release |
| | bgcolor="LightGreen" |1. Stigmata of recent hemorrhage should be recorded as they predict risk of further bleeding and guide management decisions. The stigmata, in descending
| | *Out come - Discharged home |
| risk of further bleeding, are active spurting, non-bleeding visible vessel, active oozing, adherent clot, fl at pigmented spot, and clean base .
| |
| |-
| |
| |}
| |
| | |
| == Endoscopic therapy ==
| |
| {| class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen" |'''Strong recommendation'''
| |
| |-
| |
| | bgcolor="LightGreen" |1. Endoscopic therapy should be provided to patients with active spurting or oozing bleeding or a non-bleeding visible vessel.
| |
| |-
| |
| | bgcolor="LightGreen" |2. Endoscopic therapy should not be provided to patients who have an ulcer with a clean base or a fl at pigmented spot .
| |
| |-
| |
| | bgcolor="LightGreen" |3. Epinephrine therapy should not be used alone. If used, it should be combined with a second modality.
| |
| |-
| |
| | bgcolor="LightGreen" |4. Thermal therapy with bipolar electrocoagulation or heater probe and injection of sclerosant (e.g., absolute alcohol) are recommended because they
| |
| reduce further bleeding, need for surgery, and mortality.
| |
| |-
| |
| |}
| |
|
| |
| {| class="wikitable" style="width:82%"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon" |'''Conditional recommendation'''
| |
| |-
| |
| | bgcolor="LemonChiffon" |1. Endoscopic therapy may be considered for patients with an adherent clot resistant to vigorous irrigation. Benefi t may be greater in patients with clinical features
| |
| potentially associated with a higher risk of rebleeding (e.g., older age, concurrent illness, inpatient at time bleeding began).
| |
| |-
| |
| | bgcolor="LemonChiffon" |2. Clips are recommended because they appear to decrease further bleeding and need for surgery. However, comparisons of clips vs. other therapies yield
| |
| variable results and currently used clips have not been well studied .
| |
| |-
| |
| | bgcolor="LemonChiffon" |3. For the subset of patients with actively bleeding ulcers, thermal therapy or epinephrine plus a second modality may be preferred over clips or sclerosant
| |
| | |
| alone to achieve initial hemostasis .
| |
| |-
| |
| |}
| |
| | |
| == Medical therapy after endoscopy ==
| |
| {| class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen" |'''Strong recommendation'''
| |
| |-
| |
| | bgcolor="LightGreen" |1. After successful endoscopic hemostasis, intravenous PPI therapy with 80 mg bolus followed by 8 mg/h continuous infusion for 72 h should be given to
| |
| patients who have an ulcer with active bleeding, a non-bleeding visible vessel, or an adherent clot.
| |
| |-
| |
| | bgcolor="LightGreen" |2. Patients with ulcers that have fl at pigmented spots or clean bases can receive standard PPI therapy (e.g., oral PPI once daily).
| |
| |-
| |
| |}
| |
| | |
| == Repeat endoscopy ==
| |
| {| class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon" |'''Conditional recommendation'''
| |
| |-
| |
| | bgcolor="LemonChiffon" |1. Routine second-look endoscopy, in which repeat endoscopy is performed 24 h after initial endoscopic hemostatic therapy, is not recommended.
| |
| |-
| |
| | bgcolor="LemonChiffon" |2.If further bleeding occurs after a second endoscopic therapeutic session, surgery or interventional radiology with transcathether arterial embolization is
| |
| generally employed
| |
| |-
| |
| |}
| |
| | |
| == Hospitalization == | |
| {| class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon" |'''Conditional recommendation'''
| |
| |-
| |
| | bgcolor="LemonChiffon" |1.Patients with high-risk stigmata (active bleeding, visible vessels, clots) should generally be hospitalized for 3 days assuming no rebleeding and no other
| |
| reason for hospitalization. They may be fed clear liquids soon after endoscopy.
| |
| |-
| |
| |}
| |
| | |
| {| class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen" |'''Strong recommendation'''
| |
| |-
| |
| | bgcolor="LightGreen" |1.Patients with clean-based ulcers may receive a regular diet and be discharged after endoscopy assuming they are hemodynamically stable, their hemoglobin
| |
| is stable, they have no other medical problems, and they have a residence where they can be observed by a responsible adult.
| |
| |-
| |
| |}
| |
| | |
| == Long-term prevention of recurrent bleeding ulcers == | |
| {| class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen" |'''Strong recommendation'''
| |
| |-
| |
| | bgcolor="LightGreen" |1.Patients with H. pylori -associated bleeding ulcers should receive H. pylori therapy. After documentation of eradication, maintenance antisecretory
| |
| therapy is not needed unless the patient also requires NSAIDs or antithrombotics.
| |
| |-
| |
| | bgcolor="LightGreen" |2. In patients with NSAID-associated bleeding ulcers, the need for NSAIDs should be carefully assessed and NSAIDs should not be resumed if possible. In
| |
| patients who must resume NSAIDs, a COX-2 selective NSAID at the lowest effective dose plus daily PPI is recommended.
| |
| |-
| |
| |}
| |
| | |
| {| class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon" |'''Conditional recommendation'''
| |
| |-
| |
| | bgcolor="LemonChiffon" |1.In patients with low-dose aspirin-associated bleeding ulcers, the need for aspirin should be assessed. If given for secondary prevention (i.e., established
| |
| cardiovascular disease) then aspirin should be resumed as soon as possible after bleeding ceases in most patients: ideally within 1 – 3 days and certainly
| |
| | |
| within 7 days. Long-term daily PPI therapy should also be provided. If given for primary prevention (i.e., no established cardiovascular disease), anti-platelet
| |
| | |
| therapy likely should not be resumed in most patients.
| |
| |-
| |
| | bgcolor="LemonChiffon" |2. In patients with idiopathic (non- H. pylori , non-NSAID) ulcers, long-term antiulcer therapy (e.g., daily PPI) is recommended.
| |
| |-
| |
| |}
| |
| | |
| ===References===
| |
| {{Reflist|1}}
| |